State Street Holds 9 Million CytomX Shares Without Seeking To Influence Control
The passive holding represents 4.1% of the common-stock class as CytomX prepares an approval-supporting cancer study.
State Street reported about 9 million shares in CytomX Therapeutics, which develops cancer treatments designed to activate mainly inside tumors, in a passive ownership disclosure filed Tuesday. The holding represents 4.1% of the common-stock class, and State Street certified that it was acquired and held without seeking to change or influence control.
A Passive 4.1% Holding
State Street's exact holding was 9,025,855 shares, measured as of September 30, 2026. The 4.1% figure uses the disclosure's beneficial-ownership basis rather than a percentage of shares currently outstanding.
State Street reported shared voting authority over 8,753,246 shares and shared authority to dispose of the full holding. It certified that the securities were bought and held as part of ordinary business activity.
Varseta-M's Next Clinical Step
CytomX anticipates beginning a Varseta-M study intended to support regulatory approval in the first half of 2027. The company expects its funding to last into the second half of 2028.
Its PROBODY platform masks biologic drugs to concentrate their activation in tumors rather than healthy tissue. CytomX's clinical programs are in early-stage trials: varsetatug masetecan, an antibody carrying a cancer-killing drug for colorectal cancer, and CX-801, a masked interferon alpha-2b treatment being tested in advanced melanoma.
CytomX also works with Bristol Myers Squibb and Regeneron on treatments that engage T cells, and lists alliances with Amgen, Astellas and Moderna. It aims to advance treatments independently or alongside partners.
State Street's holding is passive; CytomX's next planned clinical milestone is the approval-supporting Varseta-M study.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: CYTOMX THERAPEUTICS INC (CTMX) — SEC EDGAR
- CytomX anticipates Varseta-M registrational study in 1H 2027 while projecting cash runway into 2H 2028 (NASDAQ:CTMX) | Seeking Alpha — seekingalpha.com